Warning: The NCBI web site requires JavaScript to function. more...
Breast cancer patients with bone metastases are characterised by increased levels of nonisomerised type I collagen fragments.
Cloos PA, Christgau S, Lyubimova N, Body JJ, Qvist P, Christiansen C.
Breast Cancer Res. 2003;5(4):R103-9. Epub 2003 May 19.
Related citations
Investigation of bone disease using isomerized and racemized fragments of type I collagen.
Cloos PA, Fledelius C, Christgau S, Christiansen C, Engsig M, Delmas P, Body JJ, Garnero P.
Calcif Tissue Int. 2003 Jan;72(1):8-17. Epub 2002 Oct 21.
An immunoassay for measuring fragments of newly synthesized collagen type I produced during metastatic invasion of bone.
Cloos PA, Lyubimova N, Solberg H, Qvist P, Christiansen C, Byrjalsen I, Christgau S.
Clin Lab. 2004;50(5-6):279-89.
The amino-terminal propeptide (PINP) of type I collagen is a clinically valid indicator of bone turnover and extent of metastatic spread in osseous metastatic breast cancer.
Pollmann D, Siepmann S, Geppert R, Wernecke KD, Possinger K, Lüftner D.
Anticancer Res. 2007 Jul-Aug;27(4A):1853-62.
Collagen fragments in urine derived from bone resorption are highly racemized and isomerized: a biological clock of protein aging with clinical potential.
Cloos PA, Fledelius C.
Biochem J. 2000 Feb 1;345 Pt 3:473-80.
Alpha CTX as a biomarker of skeletal invasion of breast cancer: immunolocalization and the load dependency of urinary excretion.
Leeming DJ, Delling G, Koizumi M, Henriksen K, Karsdal MA, Li B, Qvist P, Tankó LB, Byrjalsen I.
Cancer Epidemiol Biomarkers Prev. 2006 Jul;15(7):1392-5.
Cross-linked type I collagen C- and N-telopeptides in women with bone metastases from breast cancer.
Ulrich U, Rhiem K, Schmolling J, Flaskamp C, Paffenholz I, Sälzer H, Bauknecht T, Schlebusch H.
Arch Gynecol Obstet. 2001 Jan;264(4):186-90.
Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases.
Body JJ, Lichinitser M, Tjulandin S, Garnero P, Bergström B.
Ann Oncol. 2007 Jul;18(7):1165-71. Epub 2007 Apr 17. Erratum in: Ann Oncol. 2008 Mar;19(3):601.
Urinary carboxyterminal telopeptide of collagen I as a potential marker of bone metastases chemotherapy monitoring in breast cancer.
Houzé P, Bellik B, Extra JM, Bouro F, Bousquet B.
Clin Chim Acta. 1999 Mar;281(1-2):77-88.
Urinary excretion of deoxypyridinoline in patients with breast cancer.
Nguyen-Pamart M, Bonneterre J, Hecquet B.
Anticancer Res. 1995 Jul-Aug;15(4):1601-3.
The circadian rhythm of biochemical markers of bone resorption is normally synchronized in breast cancer patients with bone lytic metastases independently of tumor load.
Generali D, Berruti A, Tampellini M, Dovio A, Tedoldi S, Bonardi S, Tucci M, Allevi G, Aguggini S, Milani M, Bottini A, Dogliotti L, Angeli A.
Bone. 2007 Jan;40(1):182-8. Epub 2006 Aug 24.
Does increased local bone resorption secondary to breast and prostate cancer result in increased cartilage degradation?
Leeming DJ, Byrjalsen I, Qvist P, Koizumi M, Lynnerup N, Fregerslev M, Sørensen MG, Christiansen C, Karsdal MA.
BMC Cancer. 2008 Jun 27;8:180.
Predictive value of osteocalcin and beta-CrossLaps in metastatic breast cancer.
Salem AM, Zohny SF, Abd El-Wahab MM, Hamdy R.
Clin Biochem. 2007 Nov;40(16-17):1201-8. Epub 2007 Aug 10.
Comparison of biochemical markers of bone resorption in patients with metabolic and malignant bone diseases.
Withold W, Friedrich W, Reinauer H.
Ann Clin Biochem. 1996 Sep;33 ( Pt 5):421-7.
Assessment of circulating Dickkopf-1 with a new two-site immunoassay in healthy subjects and women with breast cancer and bone metastases.
Voorzanger-Rousselot N, Journe F, Doriath V, Body JJ, Garnero P.
Calcif Tissue Int. 2009 May;84(5):348-54. Epub 2009 Feb 28.
Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.
Brown JE, Cook RJ, Major P, Lipton A, Saad F, Smith M, Lee KA, Zheng M, Hei YJ, Coleman RE.
J Natl Cancer Inst. 2005 Jan 5;97(1):59-69.
Comparison of serum bone resorption markers in the diagnosis of skeletal metastasis.
Koizumi M, Takahashi S, Ogata E.
Anticancer Res. 2003 Sep-Oct;23(5b):4095-9.
Markers of bone resorption--measurement in serum, plasma or urine?
Huber F, Traber L, Roth HJ, Heckel V, Schmidt-Gayk H.
Clin Lab. 2003;49(5-6):203-7.
Can bone markers guide more effective treatment of bone metastases from breast cancer?
Clemons M, Cole DE, Gainford MC.
Breast Cancer Res Treat. 2006 May;97(1):81-90. Epub 2005 Dec 1. Review.
Urinary type II collagen helical peptide (HELIX-II) as a new biochemical marker of cartilage degradation in patients with osteoarthritis and rheumatoid arthritis.
Charni N, Juillet F, Garnero P.
Arthritis Rheum. 2005 Apr;52(4):1081-90.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on